Careers  |  Sign In  |  Register  |   Twitter

Merck Cancer Immunotherapy May Hit Market Sooner than Expected

Merck & Co’s long awaited immuno-oncology drug for the treatment of melanoma may soon be approved by the FDA, an article published by Reuters reports. The preventative drug, pembrolizumab, is designed to help the body’s immune system block a protein known as PD-1, fighting cancer by shrinking tumors. Studies have shown that the drug effectively shrinks tumors in about a third of late-stage melanoma patients. In addition to the treatment of melanoma, PD-1 drugs are currently being studied for the treatment of other cancers, particularly lung cancer, which is responsible for the deaths of 160,000 Americans each year.

Read the article published by Reuters.